Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) EBT (2020 - 2025)

Historic EBT for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$7.9 million.

  • Rani Therapeutics Holdings' EBT rose 3779.28% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.6 million, marking a year-over-year increase of 1332.74%. This contributed to the annual value of -$56.6 million for FY2024, which is 1664.48% up from last year.
  • Latest data reveals that Rani Therapeutics Holdings reported EBT of -$7.9 million as of Q3 2025, which was up 3779.28% from -$11.2 million recorded in Q2 2025.
  • In the past 5 years, Rani Therapeutics Holdings' EBT ranged from a high of -$5.5 million in Q2 2021 and a low of -$28.7 million during Q3 2021
  • Moreover, its 5-year median value for EBT was -$14.1 million (2023), whereas its average is -$14.4 million.
  • Per our database at Business Quant, Rani Therapeutics Holdings' EBT plummeted by 89593.47% in 2021 and then skyrocketed by 4307.99% in 2022.
  • Rani Therapeutics Holdings' EBT (Quarter) stood at -$13.3 million in 2021, then tumbled by 30.26% to -$17.4 million in 2022, then increased by 19.15% to -$14.1 million in 2023, then decreased by 11.86% to -$15.7 million in 2024, then skyrocketed by 49.66% to -$7.9 million in 2025.
  • Its EBT was -$7.9 million in Q3 2025, compared to -$11.2 million in Q2 2025 and -$12.7 million in Q1 2025.